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Summary: Total protein content, -antitrypsin, a2-macroglobulin and plasminogen levels and measles anti-
body titers were determined in serum and plasma from patients affected with multiple sclerosis and patients
affected with non-neurological diseases.
The results were compared with those from a control group of healthy donors. Both multiple sclerosis patients
and patients affected with non-neurological diseases differed from controls for the following parameters: total
protein, plasminogen and measles antibody activity. However, when studied longitudinally the different pa-
rameters were not altered to the same degree in multiple sclerosis and non-neurological diseases, a fact which
is translated in the difference of significance levels. Individual plasminogen values were very often higher in
non-neurological diseases than in multiple sclerosis, whereas for increased measles antibody titers it was the
reverse. Also, there were no notable changes in -antitrypsin and a2-macroglobulin values in multiple sclero-
sis, whereas in some non-neurological disease patients particularly high -antitrypsin and az-macroglobulin
values were observed.
In the multiple sclerosis patients, no correlations existed between the duration of the disease and disturbed
biochemical parameters, or between the disturbed parameters themselves.
Masern-Antikörper-, Proteaseinhibitoren·^ und Plasminogen· Verteilung in Serum und Plasma bei Patienten mit
Multipler Sklerose und nicht-neurologischen Erkrankungen
Zusammenfassung: Die Konzentrationen von Gesamtprotein, cxi-Antitrypsin, ai-Makroglobulin und Plasmi-
nogen sowie die Titer der Masern-Antikörper wurden in Serum und Plasma von Patienten mit Multipler
Sklerose und nicht=neurologischen Erkrankungen bestimmt.
Die Ergebnisse wurden mit den bei Gesunden erhaltenen verglichen. Beide Gruppen von Patienten unter-
schieden sich von den Gesunden aufgrund folgender Kenngrößen: Gesamtprotein, Plasminogen und Masern-
Antikörper. Würden die unterschiedlichen Kenngrößen jedoch longitudinal verfolgt, waren sie bei Multipler
Sklerose und nicht-neurologischen Erkrankungen nicht im selben Umfang verändert, was sich in der Diffe-
renz der Signifikanzwerte ausdrückt. Die individuellen Plasminogenkonzentrationen waren bei nicht-neuro-
logischen Erkrankungen oft höher als bei Multipler Sklerose; das Gegenteil traf für die Titer der Masern-An-
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tikörper zu. Bei Multipler Sklerose wurden auch keine bemerkenswerten Änderungen der aj-Antitrypsin-
und a:-Makroglobulinkonzentration gegenüber Gesunden beobachtet, während bei nicht-neurologischen
Erkrankungen besonders hohe Werte gefunden wurden.
Bei den Patienten mit Multipler Sklerose bestand keine Korrelation zwischen der Dauer der Erkrankung und
den gegenüber Gesunden veränderten Kenngrößen sowie zwischen den veränderten Kenngrößen selbst.
Introduction
The importance of fibrin formation is not limited to
its role in extravascular thrombotic occlusion, but
the deposition of fibrin is an integral part of tissue
inflammatory response to any injury, be it traumatic,
thermal, microbial or immunological; conversely the
fibrinolysis mechanism not only plays a role in the
removal of fibrin from the vascular bed, but also in
several other biological phenomena such äs a malig-
nant transformation (1), macrophage function (1)
etc.; moreoven fibrinolysis may be considered äs a
fundamental mechanism of repair of tissue injury
(2).
Activation of the fibrinolysis enzyme System de-
pends on the presence in plasma and other body
fluids of proteolytic enzyme precursor in large quan-
tities: i.e. plasminogen or profibrinolysin. The acti-
vated protease is termed plasmin or fibrinolysin.
Plasminogen can be converted to plasmin under the
influence of a number of physiological plasminogen
activators. It has been proposed that demyelination
may be initiated by plasminogen activator released
from activated macrophages; and, on the other band,
that plasmin itself causes demyelination (3).
Neurochemical studies have also shown that there is
an increase of acid proteinase in multiple sclerosis
plaque and that the activity of neutral proteinase can
be increased in the acute phase of plaque formation
(4). Acid proteinase is one of the major intracellular
enzymes involved in the breakdown of proteins. Its
activity is elevated in a number of degenerative con-
ditions including muscular dystrophy, inflammatory
and allergic conditions (5), and experimental allergic
encephalomyelitis (6).
Demyelination, for example, represents breakdown
of myelin by proteolytic and lipolytic enzymes, al-
though the mechanisms responsible for their release
and their mode of action are unknown. In serum,
proteinases are normally inactivated by a2-macro-
globulin and -antitrypsin, which are broad spec-
trum inhibitors. It is therefore of interest to establish
whether multiple sclerosis patients present a particu-
lar profile of these parameters. Total protein, ai-an-
titrypsin, ci2-macroglobu!in, plasminogen Contents
and measles antibody titers were determined in se-
rum and plasma from patients affected with multiple
sclerosis, and from patients affected with non^neuro-
logical diseases, and the results were compäred with
those from a control group consisting of healthy
adults.
Materials and Methods
Sample donors and patients
— Control sera and plasma were obtained from 20 healthy adult
donors whose ages ranged from 22 to 55 years.
— 25 non-neurological patients were selected on the exclusion of
any neurological Symptoms, and cancer patients were also re-
jected. This disease group is very heterogeneous and includes
pancreatitis, gastric ulcers, gall bladder lithiasis, cardiovascular
syndromes, diabetes, respifatory tract infections, spondylar-
throsis and cervico-arthrosis. The ages of the patients varied
from 22 to 86 years.
— 29 patients affected with clinically confirmed multiple sclerosis
were considered; their ages ranged from 22 to 65 years and the
evolution period of the disease from 2 to 27 years. 20 Patients
displayed the classical remission-exacerbation pattern, 5 pa-
tients presented a slowly progressive and 4 an uncertain evolu-
tion.
No sex diffefentiation was made* >..
Assay procedures
Total protein was measured according to the Biuret reaction; · -
antitrypsin, az-macroglobulin were determined in single radial
immunodiffusion using NOR-Partigen plates (NOR Paftigen <xr
antitrypsin SLA 03 and NOR Partigen a2-macroglobulin SLR 03
Behringwerke AG — Marburg Lahn — Hoechst AG) arid plas-
minogen using M-Partigen plates (M-Partigen — Plasminogen
TBV 03, also from Behringwerke).
All Partigen plates were calibrated with Behringwerke Standard
serum OSMH 07 for the determination of -antitrypsin and 0:2-
macroglobulin. Behringwerke Standard plasma TFI was used for
the determination of plasminogen. Haemagglutination Inhibition
and complement fixation tests were carried out äs previously de-
scribed (7, 8).
Quality control
To guarantee the accuracy and validity of the assays 4 contfols
were used in haemagglutination Inhibition:
a) antigen control: must agglutinate at the chosen dilution
b) measles negative serum: must be void of agglutinins and non-
specific inhibitors.
c) measles positive serum: serum pool from children in the acute
phase of measles infection.
d) quality control of the red blood celtejthey must settle correctly
within 11/2 h after gentle deposition.
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In complement fixation 2 more controls wcre added:
a) control of the possible anticomplementarity activity of all sam-
plcs and the antigen.
b) validity control of the complement at the chosen dilution.
Sincc a normal distribution cannot be assumed in pathological
states, the statistical method used to compare the different popu-
lations was the non parametric U-tcst of Wilcoxon1).
The existence or non existence of correlations between the chosen
variables was determined qualitatively by scatter diagrams s re-
ported by Spiegel (9).
Results
Table l groups the results we obtained from the mul-
tiple sclerosis patients. Total protein was generally
lower than control values, cti-antitrypsin and oi2-ma-
croglobulin levels presented a distribution profile
similar to that of the control, but plasminogen dis-
played increased levels.
') Documenta Geigy — Tables scientifiques — Basel.
The distribution of measles antibody activity mea-
sured by haemagglutination Inhibition and comple-
ment fixation was completely disturbed, and in 7 pa-
tients (pat. l, 2, 14, 17, 20, 22, 29) particularly high
titers were recorded. Analysis of the results showed
no association between particularly increased plas-
minogen values and measles antibody titers (fig. 1).
Moreover, no correlation between the duration of
the disease and the disturbed plasminogen and mea-
sles antibody parameters could be detected (fig. 1).
Indeed the scatter diagrams show that the distribu-
tion of the variables is random: the points do not lie
near a line with either a positive or a negative slope;
they are uncorrelated.
Table 2 presents the parameters from the patients
affected with non-neurological diseases.
Here also total protein was generally lower than con-
trol values and αι-antitrypsin and a2-macroglobulin
distribution mainly showed profiles similar to that of
the control, with the exception of 5 especially high
Tab. 1. Plasma protein parameters and measles antibodies titers in multiple sclerosis.
Patients
n = 29
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20-
21
22
23
24
25
26
27
28
29
Duration of Evolution Total αι-Anti-
disease1) type1) protein2) trypsin2)
(years) (g/l) (g/l)
27
26
25
24
24
22
20
18
18
18
15/20*
16
14
13
12
11
10
8
7
6
6
6
6
5
4
2
u
u
u
e-r
s-P
e-r
e*r
e-r
e-r
e-r
e^-r
e-r
s^-p
s-p
e-r
e-r
e-r
e-r
u
e^f
e^f
e^r
s-p
s-p
e-r
e-r
e
e-r
e-r
u
u
u
67
61
65
63
59
61
61
59
67
nd
56
64
68
72
58
75
59
70
59
6*7
61;
67
66
74
61
73
66
68
67
4.40
2.48
3.38
3.66
2.60
3.38
2.35
2.23
3.25
nd
2.98
2.72
3.25
2.98
2.00
2.48
3.25
2.35
2,85
3.81
2.85
5.02
3.52
3.11
3.95
2.98
3.38
3.52
1.89
cu-Macro- Plasminogen Measles antibody titers
globulin2) Complement Haemagglutina-
(g/1) (mg/1) fixation tion Inhibition
4.25
1.98
2.23
2.11
2.63
2.23
1.86
2.36
1.98
nd
1.40
2.11
2.11
3.18
1.40
1.98
1.74
2.11
2.76
2.36
2.23
2.70
2.76
2.36
1.98
2.36
2.23
2.76
2.11
172
178
178
172
200
214
172
172
174
206
146
178
214
172
214
206
200
178
174
236
152
116
206
172
178
178
166
222
172
1/128
1/256
1/128
1/64
1/32
1/32
1/32
—1/256
1/16
1/16
1/32
1/32
1/256
1/128
1/128
1/128
1/64
1/64
1/256
1/16
1/256
—
1/128
1/16
1/8
1/64
1/32
1/128
1/512
1/512
1/256
1/128
1/64
1/64
1/64
1/16
1/64
1/32
1/32
1/64
1/64
1/1024
1/256
1/256
1/512
1/64
1/128
1/1024
1/32
1/2048
-
1/256
1/64
1/16
1/128
1/128
1/512
') e-r = exacerbation remission;
2) nd = not determined
*: uncertain
s-p = slowly progressive; e = exacerbation; u = unknown
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eti-antitrypsin valucs (pat. 17, 19, 22, 23, 24); how-
evcr only patients 17 and 24 combined those high
values with particularly high plasminogen levels; one
paticnt (pat. 2) also had high a:-macroglobulin lev-
ols.
Plasminogen values were generally much increased
when compared to control values and, very surpris*·
ingly, measles antibody activity was increased, espe-
cially in haemagglutination inhibition.
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Fig. l. Scatter diagrams of the variables, measles antibody activity, plasminogen levels and duration of disease in multiple sclerosis pa^
tients.
Tab. 2. Plasma protein parameters and measles antibody titers in
non-neurological patients.
Pa-
tients
n = 25
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
Total
pro-
tein
(g/l)
62
67
70
54
55
72
77
69
70
65
68
75
74
72
72
66
58
56
61
76
61
65
68
73
77
αι-Anti- ci2-Ma-
trypsin
(g/0
4.40
1.78
3.66
3.11
2.12
2.98
2.85
2.98
2.98
3.81
3.11
3.95
2.85
4.40
3.11
2.98
5.85
4.55
5.02
2.72
3.81
6.54
5.77
7.09
3.66
cro-
globulin
(g/l)
2.49
4.41
3.48
2.70
1.51
2.11
2.49
3.00
1.98
2.11
1.51
3.63
1.86
2.11
1.74
2.90
3.63
2.36
1.98
2.23
3.48
1.74
2.11
2.11
3.63
Plasmi-
nogen
(mg/1)
236
206
186
228
200
172
200
232
200
100
150
208
232
160
194
282
194
156
162
194
208
162
156
282
208
Measles antibody
titers1)
Comple-
ment
fixation
1/64
1/128
—1/32
-
—
—
1/64
1/32
1/8
—
-
nd
1/16
1/64
1/16
1/128
1/16
1/64
1/16
1/64
—1/16
"
Haemag-
glutina-
tion
inhibition
1/16
1/512
1/256
1/16
1/128
—
1/8
_
1/1024
1/32
1/128
_
1/16
nd
1/128
1/256
1/64
1/256
1/64
1/256
1/32
1/128
1/64
1/64
1/16
') nd = not determined
Finally the median values and significant differences
between the control group and p thological groups
are reported in table 3. The non-neurological disease
group significantly differed from controls for total
protein, plasminogen values and haemagglutination
inhibition measles antibody titers, whereas the mul-
tiple sclerosis group significantly differed for total
protein, plasminogen values and measles antibody ti-
ters measured by both, complement fixation and
haemagglutination inhibition.
Discussion
A general increase in plasminogen was observed in
all p thological cases, and there was no correlation
of increased plasminogen values with any particular
neurological or non-neurological disorder.
In both p thological groups the plasminogen in-
crease is most probably due to an equilibrating feed-
back System compensating for a higher demand of
turnover of plasminogen into plasmin. It is an ac-
knowledged fact that plasmin and plasminogen acti-
vators are implicated in a v riety of biological pro-
cesses (3,10,11,12). In vivo the main target of plas-
min is fibrin, which forms the fabric for cellular pn>
liferation and migration (8, 13). Several authors
have suggested that plasminogen is adsorbed to po-
'lymerizing fibrin and converted to active enzyme by
activat rs which diffuse into t^ locus of inj fy (l,
14).
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Tab. 3. Mediän valuos and significant differenccs betwcen controls and pathological samplcs for 2 = 0.01, 2 = 0.02.
Controls
Multiple sclerosis
Non-ncurological patients
N Total
protcin
(g/I)
mcdian
20 74
29 66°
25 68*
cxi-Anti-
trypsin
(g/l)
mcdian
3.32
3.10
3.66
az-Macro-
globulin
(g/l) .
median
2.36
2.23
2.23
Plasminogcn Mcasles anlibody titcrs
Complcment Haemaggluti-
fixation nation
(mg/1)
mcdian
139
178°
200*
mcdian
1/16
1/64°
1/16
Inhibi t ion
mcdian
1/16
1/128°
1/64**
0
 Multiple sclerosis values differ from controls for 2 = 0.01
* Non-neurological patients differ from controls for 2u = 0.01
** Non-neurological patients differ from controls for 2 = 0.02
There is also most probably a link with the comple-
ment cascade: the complement plays an important
role in inflammatory responses; the Splitting of €3 in
vivo by thrombin and plasmin and the conversion by
plasmin of C\ to Ci active esterase is of importance
in antibody-independent inflammatory reaction.
However äs far äs the non-neurological group is con-
cerned the plasminogen increase may also be ex-
plained by the fact that the mean age is considerably
higher than the mean age of the multiple sclerosis
group (15).
For multiple sclerosis, the increased plasminogen se-
rum levels agree with earlier findings in CSF, where
higher levels of plasminogen were found in CSF
from patients with various neurological disorders
(13, 16). The authors observed a good correlation
between CSF plasminogen values and protein con-
centrations, from which it was concluded that the
CSF plasminogen is probably derived from the
blood, rather than produced in the nervous System.
Presumably in multiple scJerosiSj the immunological
disturbances can activate the coagulation cascade,
with the consumption of fibrinogen. Consequently,
äs already stated, there will be a higher demand for
the turnover of plasmiriogeii into plasmin.
When looking at the distribution profile of ctranti-
trypsin and az-macroglobulin, a puzzling observation
is that in spite of the increased proteolytic proen-
zyme plasminogen activity, serum levels of these
proteinase inhibitors are not significantly altered in
the majority of patients.
Normally the end result of a fibrinolytic episode at
the time when all circul'ating plasmin has been inhi-
bited, will be a fall of plasminogen äs well äs plas-
minogen inhibitor levels in plasma. The reverse is al-
so true, so one should expect an increase of anti-pro-
teinase levels when plasminogen levels are in-
creased.
cti-Antitrypsin is the major broad spectrum serum
protease inhibitor in plasma; it is an important
acute-phase protein, binding and neutralizing a
ränge of proteases which are then cleared by the
RES; a2-macroglobulin, a macrophage product, par-
ticipates in this clearance, but ct2-macroglobulin
plays a more "specific role in the inactivation of plas-
min. However it reacts more slowly with plasmin
than does ai-antiplasmin and acts äs a second line
inhibitor (17, 18).
Since oti-antitrypsin plays an important role in the
modulation of inflammatory processes i t is the more
surprizing that in multiple sclerosis, where the CNS
is involved in an important inflammatory reaction,
the anti-proteinase distribution was even more regu-
lär than in the non-neurological disease group,
where iri a few patients particularly high ct|-antitryp-
sin and ctz-macroglobulin values were observed.
However, one can argue that what happens at the
peripheral blood level is no true reflection of what
happens at the cellular level. At the cellular level
there might be a local production of anti-protein-
ases, but the activity might be very different from
that found in the serum.
As far äs the measles antibody activity is concerned,
even if the general increase in measles antibody ti-
ters is more elevated in multiple sclerosis, the finding
that elevated titers do not solely appear in multiple
sclerosis, but in non-neurological diseases äs well,
adds more evidenee in favour of the hypothesis that
increase of viral antibody titers may be the result of
non specific Stimulation (19), related in some un-
known way to the disease process in the CNS; äs far
äs multiple sclerosis is concerned, it also confirms
our earlier results (20, 21).
Poskitt et al. (22) demonstrated that immunization
of single lymphnodes with various antigens led to the
appearance of cells in the afferent lymph that secret-
ed antibody specific for antigen and for a number of
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unrelated, non-crossreacting antigens. From their
observations, they concluded that the micro-envir-
onment within the lymphnode, responding to an an-
tigen, induces not only the maturation of specific an-
tigen reactive lymphocytes, but also the maturation
of lymphocytes of unrelated specificities.
Finally the longitudinal differences observed be-
tween multiple scierosis and non-neurological pa-
tients vvhich are translated by different significance
limits, indicate that in multiple scierosis, which is
primarily a demyelinating disease, the homeostatic
functions of the organism are differently altered. In-
deed, we do not know how the disturbances of the
general metabolism may influence the biochemical
function of the immune organ, but it seems that the
outstanding features of the disease in multiple scie-
rosis patients, i.e. the frequent occurrence of re-
lapses and remissions, and the liability of patients to
these relapses throughout their life, are a manifesta-
tion of particular alterations of homeostatic function.
Conclusions
1. There was no trend for the observed general plas-
minogen increase in pathological cases to be asso-
ciated with any disorder in particular, be it neuro-
logical or not. Consequently, although the acti-
vated plasminogen, plasmin, causes or may cause
demyelination, the plasminogen increase in mul-
tiple scierosis patients is still to be seen äs part of
a general and fundamental mechanism of tissue
repair versus tissue injury: but which for un-
known reasons, has its privileged area in the
CNS, and is translated by the formation of
plaques.
2. The quasi-iiormal distribution of anti-protein-
ases, and more particularly of ai-antitrypsin,
since it plays an important role in the inodulation
of inflammatory processes, is the more surprising
in multiple scierosis, where the CNS is involved in
an important inflammatory reaction.
Recent studies (23, 24) have suggested that ar
antitrypsin may have a role in the regulation of
immune responses. Studies with human lympho-
cytes implied that -antitrypsin irthibited the
proliferative responses to mitogenic Stimulation
and regulatory activity appears to be mediated
via the macrophages. According to the high mea-
sles antibody activity, found by complemerit fixa-
tion and haemagglutination Inhibition^ Inhibition
of the proliferative response to mitogenic Stimu-
lation seems not be the case in multiple scierosis.
Moreover in multiple scierosis there is also evi-
dence for aberrant immune responses that could
play a primary or secondary role in the patho-
genesis of the disease (25, 26).
Breit et al. (27) postulated. that aj-antitrypsin
might modulate the activation of T-cells through
its effect on moiiöeytes, leading to abnormality in
immunoregulation and hence a predisposition to
the development of a variety of immunologic dis-
orders in -antitrypsin deficient subjects.
Such a postulate could be accepted for multiple
scierosis but does not account for the very hetero-
geneous non-neurological group; the probability
that all non-neurological patients should present
a deficient peripheral aj-antitrypsin syüthesis is
practically nil. The answer most probafoly lies at
the cellular level, where local deficient anti-pro-
teinase production might induce a more or less
pronounced impaired capäcity for protease regu-
lation and increased tissue destruction could oc-
cur due to proteolytic damage.
3. Our finding that elevated measles antibody titers,
when they are observed, are not assöciated exclu-
sively with multiple scierosis, adds more evidence
in favour of the nori-specific mitogenic Stimula-
tion hypothesis and confirms our earlier findings:
a) in a previous paper (28) we reported the fail-
ure to detect measles antibodies in brain spec-
imens from several multiple scierosis patients.
b) in a subsequent pap.er.:.(20), isolated serum
immunoglobulins from several multiple scie-
rosis patients were investigated for the pres-
ence of measles antibodies. The results did
not provide convincing arguments for the
measles virus etiology of the disease, since
more than half the patients did not display
particülar haemagglutination Inhibition mea^·
sles antibody titers, or were even frankly neg-
ative.
We wondered whether measles virus etiology
can be generally accepted for multiple sclero^
sis, with certain patients reacting more strong-
ly to the causative agent, or whether, in cer-
tain patients, there is, next to and independ-
ent of the disease, a particular immunologica!
response to measles virus.
c) finally, in a paper on measles antibodies, ~
light chain distribution and imriiünoglobulins
in serum, CSF and brain of a patient affeeted
with multiple scierosis (21), the data as-
sembled did not add up to convincing argu-
ments for a measles vifüs^etiology. We con·?
clüded that most probably the etiology of
J. Clin. Chem. Clin. Biochem. / Vol. 22, 1984 / No. 1<0
Bollengier et al.: Disturbed serum and plasma parameters in multiple sclerosis and non-neurological diseases 659
multiple sclerosis is not specifically related to
measles antigen and agreed with Nordal (19),
that if there is local antibody production it
could well be a result of non-specific mitogen-
ic Stimulation associated in some unknown
way with the disease process in the CNS.
In multiple sclerosis patients, correlations be-
tween the duration of the disease and disturbed
parameters, and between the perturbed variables
themselves were non existent. In addition, the
disturbed parameters were not specific for multi-
ple sclerosis; only the significance limits were
specific.
The abnormalities observed in multiple sclerosis
patients may perhaps be considered äs a conse-
quence of a non-specific activation of the coagu-
lation System in a chronic immunological disease.
It becomes more and more clear that if one looks
for specificity in multiple sclerosis, it must be
looked for in the mechanisms by which the CNS
specifically becomes the "privileged" area of the
disease. The evidence for participation of im-
mune mechanisms in the pathogenesis of this
neurological disease is undisputable, but how the
mechanisms work is still an enigma.
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